One may hypothesize that the same amount of drug concentrated in the lung environment with fewer HER2-expressing cancer cells, may instead target normal epithelial cells in the tumor microenvironment (TME) that also express HER2, thereby causing pneumonitis. This evidence concerns the gene ERBB2 and pneumonitis.